$VTVT Cashflow Statement | Understand Stock

$VTVT

$25.81 +$0.26 (1.02%) Close

$VTVT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss before noncontrolling interest
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Depreciation expense
Loss on disposal of property and equipment
Loss from G42 Promissory Note early redemption
Non-cash interest income
Interest expense
Share-based compensation expense
Change in fair value of investments
Realized gain on sale of investment in Reneo Pharmaceuticals, Inc.
Impairment of investments in Anteris Bio, Inc.
Change in fair value of warrants, related party
Amortization of debt discount
Change in fair value of warrants
Related Party
Nonrelated Party
Total change in fair value of warrants

Changes in assets and liabilities:
Accounts receivable
Prepaid expenses
Long-term deposits
Other current assets
Other assets
Accounts payable and accrued expenses
Accreted interest on debt
Contract liabilities
Other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Proceed from sale of investments in Reneo Pharmaceuticals, Inc.
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from sale of Class A common stock, pre-funded and common warrants, net of offering costs
Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs
Proceeds from issuance of Class A common stock, net of offering costs
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs
Proceeds from sale of Class A common stock and warrants, net of offering costs
Proceeds from the exercise of stock options
Taxes paid related to net share settlement of equity awards
Proceeds from debt issuance
Repayment of notes payable
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents
Total cash and cash equivalents, beginning of year
Total cash and cash equivalents, end of year
Supplemental cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-cash activities:
Notes receivable recorded at fair value from collaboration partner
Change in redemption value of noncontrolling interest
Redeemable Noncontrolling Interest
Total change in redemption value of noncontrolling interest
Reclassification of noncontrolling interest to additional paid-in capital

Comments